Conexeu Sciences introduced the B.R.E.A.S.T. platform, a regenerative breast reconstruction system that uses 3D-printed extracellular matrix (ECM)-based biomaterials to support soft-tissue regeneration. The company positioned the platform as a bioresorbable scaffold designed to provide both structural and biological support while encouraging the body to gradually replace the implant with native tissue.
The technology forms part of Conexeu’s broader CXU regenerative platform and was presented alongside Ten Minute Tissue, an injectable room-temperature ECM product. The company said its approach builds on collagen technology licensed from the University of British Columbia and cited preclinical studies and proprietary research supporting the regenerative model. Conexeu also disclosed recent fundraising activity and plans for a Nasdaq direct listing involving existing shareholder sales.
For patients, the platform proposes a regenerative alternative to permanent implants by focusing on tissue remodeling rather than long-term synthetic replacement. The development reflects a broader trend toward bioresorbable and biomimetic scaffold technologies aimed at advancing reconstructive medicine through tissue regeneration.
Regenerative Breast Matrix Platforms
Conexeu Sciences Introduced Its B.R.E.A.S.T. Platform
Trend Themes
-
Bioresorbable Scaffold Platforms — A shift toward bioresorbable scaffolds that gradually transfer load to regenerated tissue could displace permanent implants by enabling staged tissue remodeling and reduced long-term complications.
-
3d-printed ECM Biomaterials — Precise 3D printing of extracellular matrix–based structures offers the potential to tailor porosity and biochemical cues for patient-specific regeneration and improved integration with native tissue.
-
Injectable Room-temperature Ecms — Room-temperature injectable ECM formulations open possibilities for minimally invasive soft-tissue augmentation with in situ remodeling and reduced procedural complexity compared with traditional implants.
Industry Implications
-
Breast Reconstruction Surgery — Reconstructive procedures could be transformed by regenerative platforms that prioritize host-mediated tissue restoration over lifelong synthetic implants, altering long-term care pathways.
-
Regenerative Medicine Biotech — Companies developing biomimetic, bioresorbable matrices may capture new therapeutic categories by combining scaffold architecture with biologically active cues for predictable tissue outcomes.
-
Medical Device Manufacturing — Manufacturers may need to integrate advanced biomaterials and additive manufacturing techniques to produce regulatory-compliant, resorbable devices with complex microarchitectures.